INT5903

From wiki-pain
Revision as of 03:02, 23 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1985
Last Reported 2006
Negated 0
Speculated 0
Reported most in Abstract
Documents 10
Total Number 14
Disease Relevance 5.71
Pain Relevance 5.45

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (MPO) extracellular space (MPO) oxidoreductase activity (MPO)
aging (MPO) nucleus (MPO) lysosome (MPO)
Anatomy Link Frequency
PMN 12
MPO (Homo sapiens)
Pain Link Frequency Relevance Heat
substance P 40 100.00 Very High Very High Very High
acular 14 99.98 Very High Very High Very High
lidocaine 12 99.08 Very High Very High Very High
Inflammation 148 97.26 Very High Very High Very High
Neuropeptide 10 95.80 Very High Very High Very High
imagery 10 95.12 Very High Very High Very High
local anesthetic 1 94.72 High High
Enkephalin 5 89.96 High High
cytokine 15 89.20 High High
Potency 1 89.20 High High
Disease Link Frequency Relevance Heat
Urological Neuroanatomy 35 100.00 Very High Very High Very High
INFLAMMATION 180 97.26 Very High Very High Very High
Bacterial Respiratory Disease 6 95.96 Very High Very High Very High
Adhesions 205 94.84 High High
Necrosis 10 91.12 High High
Cancer 10 90.76 High High
Coronary Artery Disease 2 86.24 High High
Atherosclerosis 10 71.04 Quite High
Disease 20 66.00 Quite High
Stress 5 63.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pyrrolomycin group antibiotics inhibit substance P-induced release of myeloperoxidase from human polymorphonuclear leukocytes.
Negative_regulation (inhibit) of Localization (release) of myeloperoxidase in polymorphonuclear leukocytes associated with substance p
1) Confidence 0.59 Published 1991 Journal J. Antibiot. Section Title Doc Link 1712007 Disease Relevance 0.39 Pain Relevance 0.50
Pyrrolomycin derivatives with an N-methylated pyrrole ring showed, however, a selective inhibition of the SP-induced MPO release.
Negative_regulation (inhibition) of Localization (release) of MPO associated with urological neuroanatomy and substance p
2) Confidence 0.59 Published 1991 Journal J. Antibiot. Section Abstract Doc Link 1712007 Disease Relevance 0.51 Pain Relevance 0.47
In addition, these compounds inhibited the f-Met-Leu-Phe (FMLP)-induced MPO release from PMN.
Negative_regulation (inhibited) of Localization (release) of MPO in PMN associated with urological neuroanatomy
3) Confidence 0.43 Published 1991 Journal J. Antibiot. Section Abstract Doc Link 1712007 Disease Relevance 0.44 Pain Relevance 0.50
An actinomycete metabolite designated HS3, which turned out to be identical with dioxapyrrolomycin or A1-R2081, and structurally related pyrrolomycins were found to inhibit SP-induced MPO release.
Negative_regulation (inhibit) of Localization (release) of MPO associated with urological neuroanatomy and substance p
4) Confidence 0.43 Published 1991 Journal J. Antibiot. Section Abstract Doc Link 1712007 Disease Relevance 0.44 Pain Relevance 0.51
This was in contrast to results with aseanostatin P5 which selectively inhibited FMLP-induced MPO release.
Negative_regulation (inhibited) of Localization (release) of MPO associated with urological neuroanatomy
5) Confidence 0.43 Published 1991 Journal J. Antibiot. Section Abstract Doc Link 1712007 Disease Relevance 0.49 Pain Relevance 0.45
We found that lidocaine added to human neutrophils in vitro markedly impaired the release of superoxide anion (O2-) and the granule enzymes lysozyme and myeloperoxidase after stimulation by phorbol myristate acetate or opsonized zymosan.
Negative_regulation (impaired) of Localization (release) of myeloperoxidase in neutrophils associated with lidocaine
6) Confidence 0.37 Published 1985 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 2997433 Disease Relevance 0.26 Pain Relevance 0.83
In addition, lysosomal enzyme secretion, such as elastase or myeloperoxidase as well as superoxide generation in human neutrophils were also reduced in a similar range.
Negative_regulation (reduced) of Localization (secretion) of myeloperoxidase in neutrophils
7) Confidence 0.24 Published 2006 Journal Life Sci. Section Abstract Doc Link 16360707 Disease Relevance 0 Pain Relevance 0.16
Ketorolac inhibited PMN superoxide anion generation, lysozyme release, myeloperoxidase release, adherence to plastic surfaces, and chemotaxis in response to N-formyl-methionyl-leucyl-phenylalanine (fMLP) in a dose-dependent manner.
Negative_regulation (inhibited) of Localization (release) of myeloperoxidase in PMN associated with acular
8) Confidence 0.22 Published 1992 Journal J. Leukoc. Biol. Section Abstract Doc Link 1318350 Disease Relevance 0.09 Pain Relevance 0.57
The drug inhibited lysozyme and myeloperoxidase release by PMN in response to C5a but failed to inhibit C5a stimulation of PMN in any of the other assays.
Negative_regulation (inhibited) of Localization (release) of myeloperoxidase in PMN
9) Confidence 0.22 Published 1992 Journal J. Leukoc. Biol. Section Abstract Doc Link 1318350 Disease Relevance 0.15 Pain Relevance 0.69
O2-. production and myeloperoxidase release from PMNs stimulated by FMLP was inhibited in a dose- but not time-dependent manner by both [1,8]naphthyridine derivatives, NF161 being statistically more active than NF177 (P < 0.01).
Negative_regulation (inhibited) of Localization (release) of myeloperoxidase
10) Confidence 0.10 Published 2006 Journal J Inflamm (Lond) Section Abstract Doc Link PMC1435878 Disease Relevance 0.83 Pain Relevance 0.39
In summary, our in vitro results indicate that the in vivo anti-inflammatory properties of compounds NF161 and NF177 [16,17] do not involve the COX pathway, but may be due to their anti-adhesive effects and their inhibition of O2-. production and of myeloperoxidase release, these properties being shown in vitro with steep concentration-response curves and at high concentrations.
Negative_regulation (inhibition) of Localization (release) of myeloperoxidase associated with inflammation
11) Confidence 0.10 Published 2006 Journal J Inflamm (Lond) Section Body Doc Link PMC1435878 Disease Relevance 0.48 Pain Relevance 0.12
NF161 percentage inhibition vs control was 87 ± 5% and its IC50 = 1.7 ± 0.4 × 10-5M; the inhibition of myeloperoxidase release induced by NF177 was lower (**p < 0.01; *p < 0.05: NF161 vs NF177), being 53 ± 6% and its IC50 = 1.7 ± 0.3 × 10-5M.


Negative_regulation (inhibition) of Localization (release) of myeloperoxidase
12) Confidence 0.10 Published 2006 Journal J Inflamm (Lond) Section Body Doc Link PMC1435878 Disease Relevance 0.54 Pain Relevance 0.04
Both compounds dose-dependently inhibited myeloperoxidase release evoked by 10-8M FMLP.
Negative_regulation (inhibited) of Localization (release) of myeloperoxidase
13) Confidence 0.10 Published 2006 Journal J Inflamm (Lond) Section Body Doc Link PMC1435878 Disease Relevance 0.36 Pain Relevance 0.03
Both NF161 and NF177 inhibited O2-. production and myeloperoxidase release from PMNs, challenged by FMLP, NF161 being statistically more active than NF177.
Negative_regulation (inhibited) of Localization (release) of myeloperoxidase
14) Confidence 0.10 Published 2006 Journal J Inflamm (Lond) Section Body Doc Link PMC1435878 Disease Relevance 0.70 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox